Back to feed

Blue Earth Therapeutics completes £60m Series A to accelerate development of next generation targeted radioligand therapies

🔎
Blue Earth Therapeutics
🧑
David Gauden
🤝
No items found.
Soleus Capital; Sands Capital Management; Bracco Imaging
💰
£60m
🌎
Oxford, United Kingdom
30 Oct 2024

QUICK READ

Blue Earth Therapeutics, an Oxford-based startup, has raised £60m in a Series A round led by Soleus Capital. Founded by CEO David Gauden, the company focuses on developing innovative radioligand therapies aimed at treating prostate cancer. Its platform supports high-precision treatments that deliver targeted radiation to tumours while sparing surrounding healthy organs.

The company's solutions are already progressing through clinical trials, showing promise for improved patient outcomes in prostate cancer care. The new capital will support Phase 2 studies of advanced radiopharmaceuticals, accelerating research to differentiate their therapies from first-generation treatments. Current investors include Soleus Capital, with additional participation from Sands Capital Management, Bracco Imaging, Woodline Partners, and PBM Capital.